Jean Bienaime, an Insider in BioMarin Pharmaceutical Inc. (BMRN), Unloaded 10000 shares of the Company; Bares Capital Management Has Boosted By $3.24 Million Its Waters (WAT) Position

April 25, 2018 - By Hazel Jackson

Waters Corporation (NYSE:WAT) Logo

Bares Capital Management Inc increased Waters Corporation (WAT) stake by 2.3% reported in 2017Q4 SEC filing. Bares Capital Management Inc acquired 16,771 shares as Waters Corporation (WAT)’s stock rose 3.47%. The Bares Capital Management Inc holds 745,719 shares with $144.07 million value, up from 728,948 last quarter. Waters Corporation now has $15.13B valuation. The stock decreased 7.83% or $16.42 during the last trading session, reaching $193.18. About 2.43 million shares traded or 376.41% up from the average. Waters Corporation (NYSE:WAT) has risen 28.61% since April 25, 2017 and is uptrending. It has outperformed by 17.06% the S&P500.

Since October 27, 2017, it had 0 insider buys, and 11 insider sales for $34.50 million activity. Shares for $1.08 million were sold by BEAUDOUIN MARK T. $4.34 million worth of Waters Corporation (NYSE:WAT) was sold by TERRICCIANO DAVID on Friday, December 15. 28,400 Waters Corporation (NYSE:WAT) shares with value of $6.22M were sold by Rae Elizabeth B. 1,312 shares were sold by Kelly Terrence P, worth $278,826. 9,195 shares were sold by Cassis Eugene G, worth $1.88 million on Wednesday, February 14. On Friday, March 9 the insider KUEBLER CHRISTOPHER A sold $1.48M. Khanna Rohit sold $5.33 million worth of stock or 26,913 shares.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.14, from 0.99 in 2017Q3. It increased, as 24 investors sold WAT shares while 171 reduced holdings. 61 funds opened positions while 159 raised stakes. 72.10 million shares or 2.19% less from 73.71 million shares in 2017Q3 were reported. Banque Pictet And Cie Sa reported 37,485 shares or 0.14% of all its holdings. Ubs Asset Management Americas owns 386,231 shares for 0.06% of their portfolio. Point72 Asia (Hong Kong) Limited has invested 0.05% in Waters Corporation (NYSE:WAT). Welch And Forbes Ltd Liability Co owns 5,166 shares for 0.03% of their portfolio. Ww Asset Mngmt reported 7,169 shares or 0.05% of all its holdings. The Pennsylvania-based Commonwealth Of Pennsylvania Pub School Empls Retrmt Systems has invested 0.02% in Waters Corporation (NYSE:WAT). Peak6 Invs LP invested 0% in Waters Corporation (NYSE:WAT). Lazard Asset Mgmt Limited Liability Corp invested 0% in Waters Corporation (NYSE:WAT). 5,033 are held by Comml Bank Of Stockton. Parametric Portfolio Assoc Ltd reported 191,427 shares. Jennison Associates Lc reported 10,608 shares stake. Primecap Management Ca reported 0.05% of its portfolio in Waters Corporation (NYSE:WAT). Liberty Mutual Grp Inc Asset Mngmt reported 3,181 shares. Profund Ltd Co invested 0.02% of its portfolio in Waters Corporation (NYSE:WAT). Castleark Mgmt Ltd Liability Co has invested 0.04% in Waters Corporation (NYSE:WAT).

Among 19 analysts covering Waters Corporation (NYSE:WAT), 7 have Buy rating, 0 Sell and 12 Hold. Therefore 37% are positive. Waters Corporation had 57 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Waters Corporation (NYSE:WAT) has “Hold” rating given on Monday, July 10 by Deutsche Bank. The firm has “Buy” rating given on Thursday, August 27 by Cantor Fitzgerald. The stock of Waters Corporation (NYSE:WAT) earned “Hold” rating by Zacks on Wednesday, August 26. The rating was maintained by Robert W. Baird with “Buy” on Monday, October 2. As per Tuesday, June 6, the company rating was maintained by Jefferies. The company was maintained on Wednesday, April 11 by Morgan Stanley. The firm earned “Hold” rating on Tuesday, January 23 by Cowen & Co. The firm earned “Hold” rating on Thursday, August 31 by Jefferies. The stock of Waters Corporation (NYSE:WAT) earned “Neutral” rating by Citigroup on Wednesday, July 27. The firm has “Hold” rating given on Tuesday, January 23 by Jefferies.

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical has $175 highest and $89 lowest target. $117’s average target is 44.21% above currents $81.13 stock price. BioMarin Pharmaceutical had 87 analyst reports since August 5, 2015 according to SRatingsIntel. Piper Jaffray maintained the shares of BMRN in report on Thursday, January 18 with “Buy” rating. The stock has “Buy” rating by Wedbush on Wednesday, December 20. Barclays Capital maintained the stock with “Overweight” rating in Friday, August 5 report. Cowen & Co maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Wednesday, October 18. Cowen & Co has “Buy” rating and $150.0 target. J.P. Morgan maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, July 11 with “Buy” rating. The stock has “Buy” rating by Leerink Swann on Tuesday, July 18. The firm earned “Outperform” rating on Thursday, December 14 by Wedbush. The stock has “Buy” rating by SunTrust on Thursday, October 19. The rating was maintained by Wedbush with “Hold” on Wednesday, November 15. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, February 23 report.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $14.29 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

Chief Executive Officer, Jean Bienaime is the Biomarin Pharmaceutical Inc’s insider who unloaded shares of Biomarin Pharmaceutical Inc, 10,000 to be precise. The shares were based on an average price per share of $83.6, with Jean Bienaime’s transaction valued at near $836,458 US Dollars. At the moment, she owns a total of 472,232 shares or 0.27% of the company’s market capitalization.

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on May, 3. They expect $-0.08 earnings per share, down 366.67% or $0.11 from last year’s $0.03 per share. After $-0.30 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -73.33% EPS growth.

The stock decreased 1.16% or $0.95 during the last trading session, reaching $81.13. About 752,712 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since April 25, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

Waters Corporation (NYSE:WAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts